ViaCyte Garners $15,000,000 New Financing

  • Feed Type
  • Date
    8/22/2014
  • Company Name
    ViaCyte
  • Mailing Address
    3550 General Atomics Court San Diego, CA 92121 USA
  • Company Description
    ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
  • Website
    http://www.viacyte.com
  • Transaction Type
    Debt
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor

By posting a comment, you agree to our terms and conditions.